First cooperative program between International Vaccine Institute and Translational Health Science and Technology Institute expected to help accelerate cooperation between India and IVI
IVI and the Translational Health Science and Technology Institute (THSTI) of India held a joint symposium at IVI headquarters on November 22.
The International Vaccine Institute (IVI) and the Translational Health Science and Technology Institute (THSTI) of India held a joint symposium at IVI headquarters in Seoul, Korea on November 22. More than ten speakers, including four from THSTI and other participants from the Korea Health Industry Development Institute (KHIDI) and India’s Department of Biotechnology (DBT), took part in the one-day symposium to share an overview of current research and development projects at THSTI and IVI, as well as to discuss common interests while exploring collaboration opportunities.
Prof. Gagandeep Kang, Executive Director of THSTI, introduces her organization.
Participants included Prof. Gagandeep Kang, Executive Director of THSTI and senior scientists Dr. Guruprasad Medigeshi, Dr. Susmita Chaudhuri and Dr. Arup Banerjee from THSTI; and Dr. Jerome Kim, Director General, Dr. Manki Song, Head of Clinical Research Laboratory, Dr. Anh Wartel, Head of Clinical Development and Regulatory, Dr. Viliam Pavliak, Head of Vaccine Process Development Unit and other IVI scientists. They addressed laboratory research at IVI and THSTI, as well as translational and epidemiology research at IVI. The symposium was hosted jointly by IVI and THSTI, and supported by SK Bioscience, a leading vaccine manufacturer in Korea.
Dr. Sojung An, Research Scientist of IVI’s Vaccine Process Development Unit, introduces a tuberculosis vaccine development project.
The symposium comes after the government of India became a state funder of IVI following last year’s exchange of a trilateral memorandum of understanding between IVI and the Indian Council of Medical Research, and the Department of Health and Family Welfare of the Ministry of Health and Family Welfare. The India-IVI partnership is building upon a long-standing and expanding collaboration including the development of the world’s first oral cholera vaccine ‘Shanchol’, based on IVI’s technology transfer to Shantha Biotechnics; as well as the establishment of an immuno-monitoring laboratory in India’s National Institute of Cholera and Enteric Diseases (NICED).
The joint symposium, which is the first cooperative program between THSTI and IVI, is expected to help accelerate research cooperation and broaden partnership between IVI and India, one of the world’s biggest producers and exporters of vaccines.
The Translational Health Science and Technology Institute (THSTI) is an autonomous institute of the Department of Biotechnology, Ministry of Science and Technology of India. The institute focuses on the development of products and strategies to address problems in public health in India. Under the leadership of Prof. Gagandeep Kang, the Executive Director, THSTI has four main themes, vaccines and infectious diseases, maternal and child health, non-communicable diseases and promotion of int-er-discipliniary clinical and translational research. THSTI is engaged in development of technologies pertaining to prophylaxis, treatment and diagnosis of infections caused by viruses (dengue, chikungunya, Japanese encephalitis, HIV, hepatitis E) and Mycobacterium tuberculosis. THSTI has a strong collaboration with the International AIDS Vaccine Initiative, with the joint THSTI-IAVI HIV Vaccine Translational Research programme focused research informed by and on clade C infected Indian patients.
The International Vaccine Institute (IVI) is the world’s only international organization devoted exclusively to the discovery, development and delivery of safe, effective and affordable vaccines for global public health. Established in 1997, IVI operates as an independent international organization under a treaty signed by 35 countries and the World Health Organization. The Institute conducts research in more than 30 countries throughout Asia, Africa and Latin America on vaccines against diarrheal infections, bacterial meningitis and pneumonia, as well as Japanese encephalitis and dengue fever, and develops new and improved vaccines at its headquarters in Seoul, Republic of Korea. For more information, please visit www.ivi.int.